Galmed's Aramchol boosts prostate cancer drug Xtandi's effectiveness in preclinical study, promising better treatment.

Pfizer seen as cautious Buy with 10% annual return but faces patent cliff and dividend risks

Pfizer is considered a cautious Buy, trading near its intrinsic value with an expected 10% annual return mainly from its high dividend yield. However, the company faces significant challenges including a looming patent cliff, a stretched balance shee...